Consensus Denali Therapeutics Inc.

Equities

DNLI

US24823R1059

Real-time Estimate Cboe BZX Other stock markets 12:33:03 2024-04-29 pm EDT			5-day change	1st Jan Change
15.77 ^USD	+2.20%		-1.56%	-26.65%

Apr. 09	UBS Adjusts Denali Therapeutics Price Target to $32 From $70, Maintains Buy Rating	MT
Apr. 03	Denali Therapeutics Insider Sold Shares Worth $1,896,250, According to a Recent SEC Filing	MT

Evolution of the average Target Price on Denali Therapeutics Inc.

Price target over the last 5 years

History of analyst recommendation changes

491fc67ffdeca815145aeb7eea5fbb.HU4k5KxzLpuei9eiFL7vZqtvThrOq28FJTdEknLhdNQ.Tjtm0OAAZOnv-q6QXvTCUZoZKFmH2zUxbQN18EOVRLdbflOHyBZY2PPxhg~46cc84f1814a03681fa0c9bd13332e74

Analyst Recommendations on Denali Therapeutics Inc.

UBS Adjusts Denali Therapeutics Price Target to $32 From $70, Maintains Buy Rating	Apr. 09	MT
Denali Therapeutics Insider Sold Shares Worth $1,896,250, According to a Recent SEC Filing	Apr. 03	MT
B. Riley Securities Adjusts Denali Therapeutics' Price Target to $36 From $38, Keeps Buy Rating	Feb. 28	MT
Citigroup Initiates Denali Therapeutics With Buy Rating, Price Target is $32	Dec. 13	MT
B. Riley Initiates Denali Therapeutics at Buy With $38 Price Target	23-09-06	MT
Wedbush Lowers Denali Therapeutics' Price Target to $31 From $37 Following Pipeline Updates, Keeps Outperform Rating	23-08-09	MT
Oppenheimer Adjusts Denali Therapeutics Price Target to $68 From $70, Maintains Outperform Rating	23-06-06	MT
Wedbush Trims Denali Therapeutics' Price Target to $37 From $38, Notes Slightly Higher Share Count; Keeps Outperform Rating	23-05-09	MT
Morgan Stanley Adjusts Price Target on Denali Therapeutics to $63 From $61, Maintains Overweight Rating	23-04-12	MT
Oppenheimer Adjusts Denali Therapeutics' Price Target to $70 From $85, Maintains Outperform Rating	23-03-02	MT
Morgan Stanley Adjusts Price Target on Denali Therapeutics to $61 From $65, Maintains Overweight Rating	23-03-01	MT
Evercore ISI Adjusts Price Target on Denali Therapeutics to $50 From $80, Maintains Outperform Rating	23-02-28	MT
Wedbush Lowers Denali Therapeutics' PT to $38 From $46, Keeps Outperform Rating	23-02-28	MT
SVB Securities Initiates Denali Therapeutics at Outperform With $50 Price Target	23-01-30	MT
Morgan Stanley Adjusts Price Target on Denali Therapeutics to $65 From $60, Maintains Overweight Rating	23-01-25	MT
Cowen Initiates Denali Therapeutics With Outperform Rating	22-12-05	MT
Morgan Stanley Adjusts Price Target on Denali Therapeutics to $60 From $67, Maintains Overweight Rating	22-11-08	MT
Berenberg Bank Adjusts Denali Therapeutics Price Target to $50 From $39, Maintains Buy Rating	22-11-08	MT
Wedbush Lowers Denali Therapeutics' Price Target to $46 From $48 on Increased Dilution, Keeps Outperform Rating	22-11-04	MT
BofA Securities Initiates Denali Therapeutics at Buy With $40 Price Target	22-11-02	MT
Berenberg US CEO Conference	22-11-01	FA
Berenberg Bank Initiates Coverage on Denali Therapeutics With Buy Rating, $39 Price Target	22-06-23	MT
Goldman Sachs Adjusts Denali Therapeutics Price Target to $82 From $99, Maintains Buy Rating	22-05-24	MT
Wedbush Adjusts Denali Therapeutics' Price Target to $48 From $62, Keeps Outperform Rating	22-05-06	MT
Wedbush Cuts Denali Therapeutics' Price Target to $62 From $72, Citing Expense Guidance; Outperform Rating Kept	22-03-01	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

15.43 USD

Average target price

40.27 USD

Spread / Average Target

+160.96%

High Price Target

95 USD

Spread / Highest target

+515.68%

Low Price Target

24 USD

Spread / Lowest Target

+55.54%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Denali Therapeutics Inc.

UBS
B. Riley
Citigroup
Wedbush
Oppenheimer
Morgan Stanley
Evercore ISI
SVB Securities LLC
Cowen
Berenberg Bank
BofA Securities
Goldman Sachs
SMBC Nikko
HC Wainwright
Cantor Fitzgerald

Ratings for Denali Therapeutics Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar